Identification of New Potent Acetylcholinesterase Inhibitors Using Virtual Screening and in vitro Approaches

Mol Inform. 2019 May;38(5):e1800118. doi: 10.1002/minf.201800118. Epub 2019 Feb 6.

Abstract

Acetylcholinesterase (AChE) is currently the most favorable target for the symptomatic treatment and reduction of Alzheimer's disease (AD). In order to identify new potent inhibitors of this enzyme, we describe herein a new structure-based virtual screening (SBVS) using the Institut Curie-CNRS chemical library (ICCL), which contained at the screening date 14307 compounds. The strategy undertaken in this work consisted of the use of several docking programs in SBVS calculations followed by the application of a consensus method (vSDC) and a scrupulous visual analysis. It allowed us to obtain a high degree of success, with a yield of almost 86 %, since 12 hits were identified among only 14 molecules tested in vitro. Still more remarkably, 6 of these hits were more active than galantamine, the reference inhibitor. These hits were predicted to have good ADMET properties. The two most promising compounds can serve as leads for AD treatment.

Keywords: Acetylcholinesterase; Alzheimer's disease; Virtual screening; inhibitory activity; vSDC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcholinesterase / metabolism
  • Alzheimer Disease / drug therapy
  • Alzheimer Disease / metabolism
  • Cholinesterase Inhibitors / analysis*
  • Cholinesterase Inhibitors / pharmacology
  • Drug Evaluation, Preclinical / methods*
  • Humans
  • Molecular Docking Simulation
  • Molecular Structure

Substances

  • Cholinesterase Inhibitors
  • Acetylcholinesterase